Description
Risperidone is a selective monoaminergic antagonist with high affinity for serotoninergic 5-HT2 and dopaminergic D2-receptors. It connects more with alpha 1-adrenergic receptors and lower affinity with H1-histaminergic and alpha 2-adrenergic receptors. He has no affinity for cholinergic receptors. These properties determine the low incidence of extrapyramidal side effects and extends the therapeutic effect of negative and affective symptoms of schizophrenia.
Indications
– Treatment of a broad spectrum of schizophrenic patients – first psychotic episode, relapses, chronic schizophrenia and other psychotic conditions in which positive symptoms (such as hallucinations, delusion, disturbed thinking, hostility, distrust) and/or negative symptoms (such as affective flattening, emotional and social reticence, impaired verbal fluency) are pronounced. It alleviates affective symptoms (such as depression, guilt, anxiety) associated with schizophrenia.
– Resperon is also indicated for long term treatment for prevention of relapse in patients with chronic schizophrenia.
– Resperon is indicated for treatment of mania in bipolar affective disorder. These episodes are characterized by elevated, expansive, or irritable mood state, high self-esteem, decreased need for sleep, pressure of speech, accelerated thought processes, lower attention span, impaired judgment, aggressive and/or destructive behavior.
Subject to medical prescription
Pharmaceutical form: 2 mg x 20 film-coated tablets
NHIF code: NF 528
ICD: F20.0, F20.1, F20.5, F20.6, F31.0, F31.1, F31.2
Pharmaceutical form: 3 mg x 20 film-coated tablets
NHIF code: NF 529
ICD: F20.0, F20.1, F20.5, F20.6, F31.0, F31.1, F31.2
